Since direct manipulation of either Cdkn2a or Becn1 could cause several downstream effects and/or potential tumor formation, we believe that defining specific upstream and downstream factors of the Cdkn2a-Becn1 pathway will pave the way to develop more focused treatments for obesity and metabolic diseases. This evidence concerns the gene CDKN2A and obesity due to melanocortin 4 receptor deficiency.